The latest price target for Evelo Biosciences (OTCEM:EVLO) was reported by TD Cowen on October 18, 2023. The analyst firm set a price target for $0.00 expecting EVLO to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Evelo Biosciences (OTCEM:EVLO) was provided by TD Cowen, and Evelo Biosciences downgraded their market perform rating.

The last upgrade for Evelo Biosciences Inc happened on November 1, 2021 when Chardan Capital raised their price target to $12. Chardan Capital previously had a neutral for Evelo Biosciences Inc.

The last downgrade for Evelo Biosciences Inc happened on October 18, 2023 when TD Cowen changed their price target from N/A to N/A for Evelo Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on October 18, 2023 so you should expect the next rating to be made available sometime around October 18, 2024.

While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Evelo Biosciences (EVLO) is trading at is $0.00, which is out of the analyst’s predicted range.